Treatment of schizophrenia

Let's talk dollars and sense

Peter F. Buckley

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Schizophrenia is a major neurologic illness with an impact on public health that has been unappreciated. Newer and arguably more effective medication treatments are now available and hold considerable promise. The higher up-front cost of these drugs is, on current evidence, offset by other economic advantages and, from a humanitarian perspective, by the expectation of improved patient outcome with less drug toxicity. The extent to which these drugs replace older drug treatments will be determined by the relative influences of clinical, pharmacoeconomic, mental health administrative, and advocacy factors over the coming years.

Original languageEnglish (US)
Pages (from-to)369-383
Number of pages15
JournalAmerican Journal of Managed Care
Volume4
Issue number3
StatePublished - Mar 1 1998

Fingerprint

Schizophrenia
Pharmaceutical Economics
Drug Costs
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Nervous System
Mental Health
Public Health
Economics
Therapeutics

ASJC Scopus subject areas

  • Health Policy

Cite this

Treatment of schizophrenia : Let's talk dollars and sense. / Buckley, Peter F.

In: American Journal of Managed Care, Vol. 4, No. 3, 01.03.1998, p. 369-383.

Research output: Contribution to journalArticle

Buckley, Peter F. / Treatment of schizophrenia : Let's talk dollars and sense. In: American Journal of Managed Care. 1998 ; Vol. 4, No. 3. pp. 369-383.
@article{9d2e582358fa496084ae673562aca695,
title = "Treatment of schizophrenia: Let's talk dollars and sense",
abstract = "Schizophrenia is a major neurologic illness with an impact on public health that has been unappreciated. Newer and arguably more effective medication treatments are now available and hold considerable promise. The higher up-front cost of these drugs is, on current evidence, offset by other economic advantages and, from a humanitarian perspective, by the expectation of improved patient outcome with less drug toxicity. The extent to which these drugs replace older drug treatments will be determined by the relative influences of clinical, pharmacoeconomic, mental health administrative, and advocacy factors over the coming years.",
author = "Buckley, {Peter F.}",
year = "1998",
month = "3",
day = "1",
language = "English (US)",
volume = "4",
pages = "369--383",
journal = "The American journal of managed care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "3",

}

TY - JOUR

T1 - Treatment of schizophrenia

T2 - Let's talk dollars and sense

AU - Buckley, Peter F.

PY - 1998/3/1

Y1 - 1998/3/1

N2 - Schizophrenia is a major neurologic illness with an impact on public health that has been unappreciated. Newer and arguably more effective medication treatments are now available and hold considerable promise. The higher up-front cost of these drugs is, on current evidence, offset by other economic advantages and, from a humanitarian perspective, by the expectation of improved patient outcome with less drug toxicity. The extent to which these drugs replace older drug treatments will be determined by the relative influences of clinical, pharmacoeconomic, mental health administrative, and advocacy factors over the coming years.

AB - Schizophrenia is a major neurologic illness with an impact on public health that has been unappreciated. Newer and arguably more effective medication treatments are now available and hold considerable promise. The higher up-front cost of these drugs is, on current evidence, offset by other economic advantages and, from a humanitarian perspective, by the expectation of improved patient outcome with less drug toxicity. The extent to which these drugs replace older drug treatments will be determined by the relative influences of clinical, pharmacoeconomic, mental health administrative, and advocacy factors over the coming years.

UR - http://www.scopus.com/inward/record.url?scp=0031856940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031856940&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 369

EP - 383

JO - The American journal of managed care

JF - The American journal of managed care

SN - 1088-0224

IS - 3

ER -